Odomzo (sonidegib)
- Region
- 🇪🇺 EU
- Active substance
- sonidegib
- Company
- Sun Pharmaceutical Industries Europe B.V.
- Status
- Authorised
- Therapeutic area
- Carcinoma, Basal Cell
- CHMP opinion
- Thu 25 Jun 2015
- EU approval
- Fri 14 Aug 2015
- Application
- EMEA/H/C/002839
- ATC
- L01XJ02
- Official record
- www.ema.europa.eu
Indication
Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Odomzo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.